Join

Compare · DFTX vs SGTX

DFTX vs SGTX

Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DFTX and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • DFTX is the larger of the two at $2.51B, about 43.2x SGTX ($58.2M).
  • DFTX has hit the wire 3 times in the past 4 weeks while SGTX has been quiet.
  • SGTX has more recent analyst coverage (8 ratings vs 4 for DFTX).
MetricDFTXSGTX
Company
Definium Therapeutics Inc.
Sigilon Therapeutics Inc.
Price
$23.02-2.29%
$22.53-2.57%
Market cap
$2.51B
$58.2M
1M return
-0.95%
-
1Y return
+196.46%
-
Sector
Health Care
Health Care
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
3
0
Recent ratings
4
8
SGTX

Sigilon Therapeutics Inc.

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Latest DFTX

Latest SGTX